SCHEMBL10457977

SCHEMBL10457977

CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](n3cnc4c(NC(=O)c5ccccc5)ncnc43)[C@@H](OC(=S)N3CCS(=O)(=O)CC3)C2O[Si](C(C)C)(C(C)C)O1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 1/20 0.40
▸ PDE4A P27815 2/20 0.39
▸ PDE4D Q08499 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ ADRB3 P13945 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ P2RY12 Q9H244 6/20 0.36
▸ P2RY2 P41231 1/20 0.34
▸ P2RY1 P47900 1/20 0.34
▸ P2RY6 Q15077 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10457913 0.91 PDE4A (0.41) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL20346094 0.91 PDE4A (0.41) PDE4APDE4DCYP1A2HTR1ACYP2D6
SCHEMBL25966452 0.89 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL10457978 0.88 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL22984002 0.85 PRMT6 (0.40) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL29674494 0.85 PRMT6 (0.40) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL19509816 0.83 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C
SCHEMBL19509705 0.83 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C
SCHEMBL10459187 0.83 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C
SCHEMBL29772235 0.83 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2018-07-05 — — US disclosed
US-9896472-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2018-02-20 — — US disclosed
US-9273086-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2016-03-01 — — US disclosed
US-20160002282-A1 Protected Monomer and Method of Final Deprotection for RNA Synthesis AGILENT TECHNOLOGIES, INC. 2016-01-07 — — US disclosed
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-11-15 — — US disclosed
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, SNRPB2, RNGTT PRMT6 897/4885PDE4A 4353/4885PDE4D 4749/4885
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, RNGTT, RNMT PRMT6 546/4885PDE4A 3652/4885PDE4D 4148/4885
US-20160002282-A1 Protected Monomer and Method of Final Deprotection for RNA Synthesis NSUN2, SNRPB2, RNGTT PRMT6 897/4885PDE4A 4353/4885PDE4D 4749/4885
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS RNMT, RNGTT, NSUN2 PRMT6 578/4885PDE4A 4102/4885PDE4D 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback